Reference/Dual GH secretagogue combination

Tesa/IPA Protocol

Tesamorelin + Ipamorelin GH Secretagogue Blend

Human clinical

research use only

The Tesa/IPA blend combines two complementary growth hormone secretagogues: Tesamorelin (a GHRH analog that stimulates GH release from the pituitary) and Ipamorelin (a selective ghrelin mimetic/GHRP that amplifies GH pulses). This combination addresses both the GHRH and GHRP pathways for synergistic GH release. Common formulations include 5mg/5mg (1:1 ratio) and 10mg/3mg (higher Tesamorelin) variants. Tesamorelin is FDA-approved for HIV-associated lipodystrophy, while Ipamorelin remains investigational.

Synergistic GH release from dual pathwaysMore physiological pulsatile GH secretionTesamorelin's proven lipodystrophy benefitsIpamorelin's clean side effect profile

2 citations·1 with human data·Updated 10 Aug 2026

Overview

The blend leverages two distinct GH-releasing pathways: Tesamorelin is a synthetic GHRH analog that directly stimulates growth hormone-releasing hormone receptors on pituitary somatotrophs, triggering GH synthesis and secretion in a pulsatile, physiological manner. Ipamorelin is a selective ghrelin receptor (GHS-R1a) agonist that amplifies GH pulses without significantly affecting cortisol or prolactin. Together, they produce synergistic GH release greater than either compound alone, while maintaining the body's natural feedback mechanisms.

Evidence profilederived from 2 references

Human clinical

Strongest design among the references on this page. Grade and effect size are separate facts and are never merged into one score.

Research indications

What the compound has been studied for, grouped by body system. Effect size is the reported magnitude where it was measured — not a recommendation.

Body Composition3

Fat Reduction

Tesamorelin has demonstrated fat reduction in clinical trials; synergy with Ipamorelin may enhance effects.

Moderate

Visceral Fat Loss

Tesamorelin specifically reduces visceral adipose tissue (FDA-approved indication).

Large

Lean Mass Support

Enhanced GH promotes protein synthesis and lean tissue preservation.

Small

Recovery & Wellness3

Sleep Quality

GH secretagogues often improve deep sleep quality.

Moderate

Recovery Enhancement

Enhanced GH supports tissue repair and recovery from exercise.

Small

Anti-Aging Support

Restoring more youthful GH levels may provide anti-aging benefits.

Small

Metabolic Health2

Lipid Profile

Tesamorelin has shown improvements in lipid parameters in studies.

Small

IGF-1 Optimization

Increased GH leads to increased IGF-1 production.

Moderate

A large effect in a weak study and a small effect in a strong one are different things. Effect size is never evidence of use in people.

Quick factsreference only

Class: Dual GH secretagogue combination
Typical dose: 200-500mcg total blend per injection
Frequency: Once daily (evening preferred) or twice daily for advanced protocols
Cycle length: 8-16 weeks continuous
Storage: Reconstituted: 2-8°C, use within 4-6 weeks

Molecular data

Type: Dual GH secretagogue combination

Dosing reference

Doses reported in the literature and by suppliers. These are a record of what has been used in research — reference, never instruction.

Context	Route	Amount	Frequency
Standard protocol (5/5 blend)	SubQ	200-400mcg total	Once daily (evening)
Enhanced protocol (10/3 blend)	SubQ	300-500mcg total	Once daily (evening)
Twice daily (advanced)	SubQ	200-300mcg per dose	Morning and evening

Interactions

Tesamorelin (standalone)

Already contains Tesamorelin - do not add more.

avoid

Ipamorelin (standalone)

Already contains Ipamorelin - do not add more.

avoid

CJC-1295

Both Tesamorelin and CJC-1295 are GHRH analogs; combining may cause excessive stimulation.

monitor

GHRP-6/GHRP-2

Already has GHRP pathway covered by Ipamorelin; adding more GHRPs may be excessive.

monitor

MK-677

Both affect GH release; combination may be excessive and affect glucose.

monitor

BPC-157

Different mechanisms; can complement for healing with GH support.

compatible

Semaglutide

Different pathways; some combine for body composition goals.

compatible

Insulin

GH affects glucose metabolism; diabetics should monitor carefully.

monitor

Quality checklist

✓Third-party testing confirming both components
✓Certificate of Analysis with ratios verified
✓Reputable research supplier
✓Proper cold chain shipping
!Tesamorelin is FDA-approved as Egrifta - research blends are not
!Ipamorelin remains investigational
×No Certificate of Analysis
×Cannot verify Tesamorelin:Ipamorelin ratio
×Discolored or particulate solution

What to expect

Week 1-2Improved sleep quality often noticed first; initial GH response

Week 2-4Enhanced recovery; subtle body composition changes beginning

Week 4-8Noticeable fat loss (especially visceral); improved energy

Week 8-16Full body composition benefits; continued improvements

Safety

Commonly reported5

Injection site reactions (redness, itching)
Water retention (usually transient)
Tingling or numbness in extremities
Joint stiffness
Increased hunger (Ipamorelin effect)

Stop and seek advice5

Severe injection site reactions
Significant swelling or edema
Signs of glucose dysregulation
Severe joint pain
Allergic reactions

Contraindications5

Active malignancy (GH may promote tumor growth)
Diabetic retinopathy
Pregnancy or breastfeeding
Pituitary disorders
Hypersensitivity to components

FAQ

Why combine tesamorelin and ipamorelin instead of using them separately?

Tesamorelin and ipamorelin work on complementary GH-release pathways (GHRH vs GHRP receptors), producing synergistic GH release greater than either alone. The combination mimics natural pulsatile GH secretion more effectively while maintaining safety with less cortisol/prolactin elevation than GHRPs used solo.

What's the ideal 5/5 vs 10/3 ratio for Tesa/IPA and when to use each?

5/5 (equal parts) provides balanced GH stimulation suitable for general recovery. The 10/3 (higher tesamorelin) variant emphasizes visceral fat loss and metabolic effects. Choose 5/5 for athletic recovery; 10/3 for fat-loss focused protocols with body composition optimization goals.

Should the Tesa/IPA blend be taken on an empty stomach?

Yes, both tesamorelin and ipamorelin work best on an empty stomach (2-3 hours before eating). Evening injection (before bed) on an empty stomach optimizes the protocol by aligning with natural nighttime GH pulses and avoiding food-induced metabolic interference.

Can Tesa/IPA be combined with CJC-1295 or other GH secretagogues?

No, combining Tesa/IPA (which already contains both GHRH and GHRP pathways) with additional GHRPs or GHRH analogs risks excessive pituitary stimulation. The blend is specifically designed as a complete dual-pathway system that shouldn't require additional GH secretagogues.

References

1
Ipamorelin, the first selective growth hormone secretagogue
Raun K, Hansen BS, Johansen NL, et al. · European Journal of Endocrinology · 1998
Ipamorelin is the first GHRP-receptor agonist with selectivity for GH release similar to GHRH; does not release ACTH or cortisol even at doses over 200-fold the ED50 for GH.
reviewPubMed 9849822 ↗
2
Metabolic effects of a growth hormone-releasing factor in patients with HIV
Falutz J, Allas S, Blot K, et al. · New England Journal of Medicine · 2007
Landmark RCT in 412 HIV patients: tesamorelin 2 mg daily for 26 weeks reduced visceral fat by 10.9% vs 0.6% placebo, improved lipid profiles with no change in subcutaneous fat.
human-rctPubMed 18057338 ↗